CA2318260A1 - Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis - Google Patents

Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis Download PDF

Info

Publication number
CA2318260A1
CA2318260A1 CA002318260A CA2318260A CA2318260A1 CA 2318260 A1 CA2318260 A1 CA 2318260A1 CA 002318260 A CA002318260 A CA 002318260A CA 2318260 A CA2318260 A CA 2318260A CA 2318260 A1 CA2318260 A1 CA 2318260A1
Authority
CA
Canada
Prior art keywords
leishmaniasis
treatment
oral administration
solid pharmaceutical
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002318260A
Other languages
French (fr)
Other versions
CA2318260C (en
Inventor
Jurgen Engel
Werner Sarlikiotis
Thomas Klenner
Peter Hilgard
Dieter Sauerbier
Eckhard Milsmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KNIGHT THERAPEUTICS (BARBADOS) Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2318260A1 publication Critical patent/CA2318260A1/en
Application granted granted Critical
Publication of CA2318260C publication Critical patent/CA2318260C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to new solid pharmaceutical compositions containing hexadecylphosphocholine (miltefosine) for oral administration in the treatment of leishmaniasis, a process for the manufacture of said pharmaceutical composition, a dosage scheme for oral administration of said pharmaceutical composition in the treatment of leishmaniasis, and finally a combination comprising said solid pharmaceutical composition, an antiemeticum, and/or an antidiarrhoeal.
CA002318260A 1998-01-22 1998-01-22 Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis Expired - Fee Related CA2318260C (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1998/000345 WO1999037289A1 (en) 1998-01-22 1998-01-22 Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis

Publications (2)

Publication Number Publication Date
CA2318260A1 true CA2318260A1 (en) 1999-07-29
CA2318260C CA2318260C (en) 2006-11-21

Family

ID=8166843

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002318260A Expired - Fee Related CA2318260C (en) 1998-01-22 1998-01-22 Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis

Country Status (24)

Country Link
US (1) US6544551B1 (en)
EP (1) EP1051159B1 (en)
JP (1) JP2002501015A (en)
KR (1) KR100517399B1 (en)
CN (1) CN100413492C (en)
AT (1) ATE215817T1 (en)
AU (1) AU756805B2 (en)
BR (1) BR9814772A (en)
CA (1) CA2318260C (en)
CZ (1) CZ299229B6 (en)
DE (1) DE69804865T2 (en)
DK (1) DK1051159T3 (en)
ES (1) ES2175663T3 (en)
HU (1) HUP0004363A3 (en)
IL (1) IL136196A (en)
NO (1) NO20003674L (en)
NZ (1) NZ505648A (en)
PL (1) PL189654B1 (en)
PT (1) PT1051159E (en)
SI (1) SI1051159T1 (en)
SK (1) SK284839B6 (en)
TR (1) TR200001717T2 (en)
UA (1) UA68372C2 (en)
WO (1) WO1999037289A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7887817B2 (en) * 2002-01-25 2011-02-15 Aeterna Zentaris Gmbh Process for preventing protozoal diseases
DE10203195A1 (en) * 2002-01-25 2003-08-07 Zentaris Ag Use of alkylphosphocholines in the preventive treatment of protozoal diseases
BR0215680A (en) * 2002-04-26 2005-02-01 Rudolf Perl Stable oral pharmaceutical composition
US8383605B2 (en) 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
CN1302780C (en) * 2002-07-30 2007-03-07 赞塔里斯有限公司 Use of alkyl phosphocholines in combination with antitumor medicaments
SI1663197T1 (en) 2003-09-09 2008-06-30 Biogen Idec Internat Gmbh The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
PL1799196T3 (en) 2004-10-08 2016-12-30 Controlled release pharmaceutical compositions comprising a fumaric acid ester
US8703179B2 (en) * 2006-05-11 2014-04-22 Kimberly-Clark Worldwide, Inc. Mucosal formulation
WO2010020276A1 (en) * 2008-08-19 2010-02-25 Orphanidis Pharma Research Gmbh Treatment of coccidian parasites
MX2011011596A (en) 2010-03-31 2012-02-01 Keryx Biopharmaceuticals Inc Perifosine and capecitabine as a combined treatment for cancer.
US9358244B2 (en) 2010-11-22 2016-06-07 Oblita Therapeutics Bvba Solid dosage forms of oleyl phosphocholine
US9949996B2 (en) 2011-06-24 2018-04-24 Gri Bio, Inc. Prevention and treatment of inflammatory conditions
JP2016515602A (en) * 2013-04-08 2016-05-30 アカデミッシュ メディッシュ セントラム Miltefosine or perifosine for use in the treatment of IBD
CA2961445C (en) 2014-09-17 2019-03-26 Babu Padmanabhan Effervescent composition and method of making it
CN104473941A (en) * 2014-12-20 2015-04-01 长沙佰顺生物科技有限公司 Miltefosine-containing medicine preparation and preparation method thereof
US11219594B2 (en) 2015-12-12 2022-01-11 Steerlife India Private Limited Effervescent compositions of metformin and processes for preparation thereof
HRP20241585T1 (en) * 2019-04-12 2025-01-31 Oblita Therapeutics Bvba PHOTO-DEPOSITION OF METAL OXIDES FOR ELECTROCHROME DEVICES

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE888444C (en) * 1951-11-10 1953-08-31 Benckiser Gmbh Joh A Process for tableting hygroscopic preparations
IE59777B1 (en) * 1985-12-04 1994-04-06 Max Planck Gesellschaft Medicaments
US4762658A (en) * 1986-10-08 1988-08-09 Central Soya Company, Inc. Method of tableting of de-oiled phosphatides (lecithin)
US5290769A (en) * 1989-09-27 1994-03-01 Asta Pharma Aktiengesellschaft Use of hexadecylphosphocholine for the treatment of psoriasis
EP0916343A1 (en) * 1989-09-27 1999-05-19 ASTA Medica Aktiengesellschaft use of alkzl phosphoric acid compounds for the treatment of psoriatic diseases
DE4132344A1 (en) * 1991-09-27 1993-04-01 Max Planck Gesellschaft METHOD FOR PRODUCING A MEDAL FOR ORAL OR TOPICAL ADMINISTRATION IN THE TREATMENT OF LEISHMANIASIS

Also Published As

Publication number Publication date
ATE215817T1 (en) 2002-04-15
NO20003674D0 (en) 2000-07-18
DE69804865D1 (en) 2002-05-16
CA2318260C (en) 2006-11-21
KR20010034311A (en) 2001-04-25
ES2175663T3 (en) 2002-11-16
PT1051159E (en) 2002-09-30
KR100517399B1 (en) 2005-09-28
WO1999037289A1 (en) 1999-07-29
IL136196A (en) 2004-07-25
CN100413492C (en) 2008-08-27
HUP0004363A3 (en) 2002-12-28
PL342838A1 (en) 2001-07-16
IL136196A0 (en) 2001-05-20
CZ299229B6 (en) 2008-05-21
CZ20002596A3 (en) 2000-10-11
HUP0004363A2 (en) 2001-04-28
JP2002501015A (en) 2002-01-15
CN1283111A (en) 2001-02-07
BR9814772A (en) 2000-10-24
AU6212198A (en) 1999-08-09
AU756805B2 (en) 2003-01-23
US6544551B1 (en) 2003-04-08
SI1051159T1 (en) 2002-10-31
NO20003674L (en) 2000-07-18
UA68372C2 (en) 2004-08-16
DE69804865T2 (en) 2002-11-07
DK1051159T3 (en) 2002-08-05
PL189654B1 (en) 2005-09-30
EP1051159B1 (en) 2002-04-10
TR200001717T2 (en) 2000-11-21
SK284839B6 (en) 2005-12-01
SK9862000A3 (en) 2000-11-07
NZ505648A (en) 2002-10-25
EP1051159A1 (en) 2000-11-15

Similar Documents

Publication Publication Date Title
CA2318260A1 (en) Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis
CA2315767A1 (en) Autoclavable pharmaceutical compositions containing a chelating agent
CA2318128A1 (en) Oral liquid compositions
PL334566A1 (en) Treatment of sclerosis multiplex by oral and inhalatory administration of a copolymer-1
ZA969248B (en) New aminoacid derivatives process for the manufacture thereof and pharmaceutical compositions containing thesse compounds
BG104727A (en) Pharmaceutical composition of topiramate
CA2238271A1 (en) Pharmaceutical compositions comprising flurbiprofen
YU21999A (en) Pharmaceutical compositions and procedure for the production thereof
BG105292A (en) Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
BG105173A (en) Novel salt form of pantoprazole
CA2343732A1 (en) Substituted .gamma.-phenyl-.delta.-lactones and analogs thereof and uses related thereto
CA2335551A1 (en) Thyroid hormone analogues and methods for their preparation
JPS57165312A (en) Production of oral composition
IE852927L (en) Preparation of silibinin
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
CA2184594A1 (en) Antitussive composition containing an antitussive and benzydamine
IL111805A0 (en) Pharmaceutical compositions comprising dimeticone for the treatment of aphthae
HUP0102609A3 (en) N-phenyl-n'-phenylpropylpiperazine derivatives and process for the preparation thereof, and pharmaceutical compositions containing them
BG104673A (en) Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis
HUT46364A (en) Process for producing 1,12-dihydroxy-1,6,12,13-tetraaza-dicyclodocosane-2,5,13,16-tetron and pharmaceutical compositions comprising this compound as active ingredient
ZA941196B (en) Angiopeptin cyclopeptide compounds process for the preparation thereof and pharmaceutical compositions containing them
HU9502509D0 (en) Use of 1,4-dihydropyridine-3,5-dicarboxylic-acid-esters as active component of pharmaceutical compositions
MX9600165A (en) 3-alkoxycarbonylthiadiazinonas, process for the preparation thereof and pharmaceutical compositions containing them.
HUP0401912A3 (en) Pharmaceutically acceptable salts of 20(s)-camptothecins, process for their preparation and pharmaceutical compositions containing them
IL142112A0 (en) Pharmaceutical compositions based on alpha-cyclodextrin for the oral administration of lh-rh analogues

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20180122